Immunogenicity and safety of a recombinant adenovirus type-5 COVID-19 vaccine in adults: Data from a randomised, double-blind, placebo-controlled, single-dose, phase 3 trial in Russia.
PloS one(2023)
摘要
Trial registration: ClinicalTrials.gov: NCT04540419.
更多查看译文
关键词
vaccine,double-blind,placebo-controlled,single-dose
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要